Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events
Abstract This analysis sought to assess the clinical predictivity of an in vitro assay which utilized the human B‐lymphoma BJAB cell line, for identification of antisense oligonucleotides (ASOs) with the potential to elicit innate immune activation in humans. Adverse events (AEs) from clinical trial...
Saved in:
Main Authors: | Wesley Partridge (Author), Sebastien A. Burel (Author), Annie Ferng (Author), Shuting Xia (Author), T. Jesse Kwoh (Author), Scott P. Henry (Author), Brenda F. Baker (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling
by: Annie Moisan, et al.
Published: (2017) -
A Sensitive Assay System To Test Antisense Oligonucleotides for Splice Suppression Therapy in the Mouse Liver
by: Lorena Gallego-Villar, et al.
Published: (2014) -
Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
by: Maaike van Putten, et al.
Published: (2014) -
Antisense Therapy
Published: (2019) -
Ranking Adverse Drug Reactions With Crowdsourcing
by: Gottlieb, Assaf, et al.
Published: (2015)